La Société Sauermann, cliente du Groupe Vidon, Lauréat Brevets des Trophées de l’Innovation INPI 2013 – lle de France
La Société Sauermann, qui conçoit et fabrique des pompes de relevage de condensats, a été désignée Lauréat Brevets des Trophées de l’Innovation 2013, pour la région Ile de France, et concourt donc désormais pour le titre au niveau national.
A cette occasion, Monsieur Chauvin, Directeur R&D, a souligné la nécessité de la Propriété Industrielle dans le développement et la pérennité de la Société, et l’importance de la coopération avec ses Conseils en PI pour établir de façon efficace les stratégies de PI adaptées, en lien avec les stratégies de développement de la Société.
Ludovic Bioret était présent, pour féliciter de vive voix le Lauréat. Le Groupe Vidon dans son ensemble félicite à nouveau la Société Sauermann pour cette récompense prestigieuse.
Introduction of the administrative action for revocation and invalidity in France
The current health crisis does not prevent the long-awaited launch of the administrative procedure for invalidity and revocation in France.
The major innovation of the “PACTE” law on trademarks, came into force on 1 April 2020: with the creation of a "Cancellation" cell within the French Office, it is now possible to bring an action for a declaration of invalidity or revocation in the form of an administrative procedure.
Revision of European Patent Office’s fees with effect from 1 April, 2020
The EPO has announced a revision of fees which will enter into force on 1 April 2020. This revision involves main fees (filing fee, search fee, examination fee, grant fee) as well as annual fees.
It is possible to arrange advanced payment of fees in the coming weeks (annual fees, examination fee, grant fee) and pay before 31, March 2020 in order to benefit from the current rate.
Feel free to contact us, we are at your disposal to assist you in the management of your patent rights.
Specific exemption: a necessity for pharmaceutical trademarks?
Specific exemption: a necessity for pharmaceutical trademarks?
Clinical trial, Marketing Authorization Application and genuine use of a trademark.
Should pharmaceutical trademarks benefit of a specific exemption for demonstrating their genuine use ?
(Copyright free taken from data base pxhere.com)
The Court of Justice of the European Union (CJEU) confronts its traditional case law to the particular frame of pharmaceutical trademarks’ genuine use appreciation.
Traditionally, case law established a relative tolerance to the condition of genuine use since the latter can be recognized for goods and services whose commercialization is not effective yet, but under way (CJEC, Ansul, March 11th, 2003, C-40/01).
Besides, it has already been specified that only obstacles that present a relation sufficiently direct with a trademark making impossible or unreasonable its useand that are independent from the will of the trademark’s owner can be qualified as “proper reasons” for non-use.
VIDON Group supportive of China
At the beginning of the New Lunar Year of the Rat’s, China is experiencing exceptional health measures.
Following the traditional Spring Festival Holidays, the resumption of work was postponed by the authorities to Monday, February 10, 2020 for the city of Shanghai.
During this period, Vidon Shanghai and its teams are committed to continuing to assist ou clients, in accordance with the exceptional measures, and stay at your disposal.
VIDON Group, in solidarity with China